CorMedix

CRMD · Nasdaq · United States

Share price · CRMD

$4.50-3.67 (-44.92%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.6M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CRMD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026-25.5%

    Nothing announced by CRMD that day or the session before.

  2. 29 Oct 2026-6.8%
  3. 14 Aug 2026-7.4%
  4. 13 Aug 2026+14.6%
  5. 1 Jul 2026+7.9%
  6. 25 Jun 2026-8.0%
  7. 18 May 2026+4.8%
  8. 14 May 2026+5.7%
  9. 27 Apr 2026+5.4%
  10. 8 Jan 2026-32.8%

Share of unusual movement by asset

For each asset, the share of CRMD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—57%
Sessions with no dated event—43%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Taurolidine/heparin(Defencath / Neutrolin)
Approved
Antimicrobial/antithrombotic catheter lock solutionSmall molecule
Chronic Kidney Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Taurolidine/heparin · Defencath / NeutrolinPhase 3Central Line Associated Blood Stream Infections (CLABSI)
Est. primary completion 2028-01 · NCT06822426 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$55M$7.0M$356M+ $0 short-term inv.$15M$90M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$6.7M$258M+ $0 short-term inv.—$86M operating cash flowreport ↗
2026-Q1—$7.2M$179M+ $0 short-term inv.—$42M operating cash flowreport ↗
2025-Q3$104M$5.1M$49M+ $7.2M short-term inv.—$31M operating cash flowreport ↗
2025-Q2$40M$2.4M$159M+ $31M short-term inv.—$30M operating cash flowreport ↗
2025-Q1$39M$3.2M$66M+ $11M short-term inv.—$20M operating cash flowreport ↗
2024-Q3$11M$0.7M$35M+ $11M short-term inv.$2.8M-$14M operating cash flowreport ↗
2024-Q2$0.8M$0.7M$29M+ $17M short-term inv.$14M-$14M operating cash flowreport ↗
2024-Q1—$0.8M$35M+ $23M short-term inv.$14M-$17M operating cash flowreport ↗
2023-Q3—$2.7M$54M+ $33M short-term inv.$9.7M-$8.7M operating cash flowreport ↗
2023-Q2—$4.8M$20M+ $33M short-term inv.$11M-$8.6M operating cash flowreport ↗
2023-Q1—$3.4M$26M+ $30M short-term inv.$11M-$10M operating cash flowreport ↗
2022-Q3<$0.1M$2.3M$43M+ $16M short-term inv.$6.8M-$6.0M operating cash flowreport ↗
2022-Q2<$0.1M$3.2M$49M+ $16M short-term inv.$7.6M-$5.5M operating cash flowreport ↗
2022-Q1<$0.1M$2.3M$46M+ $16M short-term inv.$7.0M-$6.7M operating cash flowreport ↗
2021-Q3<$0.1M$4.7M$67M+ $5.7M short-term inv.$8.6M-$5.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$312M$19M$146M+ $3.7M short-term inv.—$175M operating cash flowreport ↗

For the full year 2025, CorMedix reported revenue of $311.71M, up 617.1% YoY, with R&D spend of $19.33M, up 390.6% YoY. Cash and equivalents stood at $145.82M, and the company recorded net income of $163.06M.

CorMedix reiterated 2026 guidance of net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M. Clinical milestones include Phase 3 ReSPECT data for REZZAYO expected in Q2 2026, and an ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients with targeted completion in the first half of 2027. The company also highlighted the integration of its August 2025 Melinta acquisition and a newly authorized $75M share repurchase program.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$43M$3.9M$41M+ $11M short-term inv.$4.5M-$51M operating cash flowreport ↗
2023-FY—$13M$44M+ $32M short-term inv.$12M-$38M operating cash flowreport ↗
2022-FY$0.1M$11M$43M+ $16M short-term inv.$7.4M-$24M operating cash flowreport ↗
2021-FY$0.2M$13M$54M+ $12M short-term inv.$7.0M-$21M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($513K), 7 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Kaplan Myron · directorOpen-market purchase25,000$4.88$122KForm 4
2026-11-13Todisco Joseph · director, Chief Executive OfficerOpen-market purchase80,000$4.89$391KForm 4
2026-09-18Dillione Janet · directorOption exercise48,909——Form 4
2026-09-18Dillione Janet · directorOption exercise (derivative)48,909——Form 4
2026-08-29Zelnick Kaufman Beth · Chief Legal OfficerTax withholding8,424$8.30$70KForm 4
2026-08-29Hurlburt Elizabeth · Chief Operating OfficerTax withholding8,076$8.30$67KForm 4
2026-08-29Blum Susan · Chief Financial OfficerTax withholding8,424$8.30$70KForm 4
2026-02-04Todisco Joseph · director, Chief Executive OfficerAward / grant77,156——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 185 reporting institutions held 40.6M shares ($272.6M, 52.0% of shares outstanding).

#InstitutionSharesValue
1Deep Track Capital, LP6,274,076$42.6M
2BlackRock, Inc.5,967,575$40.5M
3VANGUARD CAPITAL MANAGEMENT LLC3,129,656$21.3M
4STATE STREET CORP2,191,843$14.9M
5ROYCE & ASSOCIATES LP1,887,532$12.8M
6GEODE CAPITAL MANAGEMENT, LLC1,816,907$12.3M
7UBS Group AG1,538,245$10.4M
8OBERWEIS ASSET MANAGEMENT INC/1,211,115$8.2M
9Alyeska Investment Group, L.P.850,000$5.8M
10VANGUARD PORTFOLIO MANAGEMENT LLC742,571$5.0M
11KENNEDY CAPITAL MANAGEMENT LLC673,302$4.6M
12NORTHERN TRUST CORP637,683$4.3M
13Palisades Investment Partners, LLC610,148$4.1M
14CHARLES SCHWAB INVESTMENT MANAGEMENT INC602,966$4.1M
15Trexquant Investment LP560,637$3.8M